These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 2228826

  • 1. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE, Henderberg A, Sanders CV.
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW, Weeks LS, Aldridge KE.
    Diagn Microbiol Infect Dis; 1992 Sep; 15(4):321-30. PubMed ID: 1611847
    [Abstract] [Full Text] [Related]

  • 3. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC, Spangler SK, Jacobs MR.
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [Abstract] [Full Text] [Related]

  • 4. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE.
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [Abstract] [Full Text] [Related]

  • 5. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ, Citron DM.
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [Abstract] [Full Text] [Related]

  • 6. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C, Sánchez A, Gómez M, Palau ML, Picazo JJ.
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL.
    Diagn Microbiol Infect Dis; 1989 Jan; 12(1):39-43. PubMed ID: 2714071
    [Abstract] [Full Text] [Related]

  • 9. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM, Lamothe F, Hoban DJ, Dalton MT, Kibsey PC, Harding G, Smith JA, Low DE, Gilbert H.
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [Abstract] [Full Text] [Related]

  • 10. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ.
    Pharmacotherapy; 1991 Feb; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
    Aldridge KE, Stratton CW.
    J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.
    Johnson CC.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S371-6. PubMed ID: 8324150
    [Abstract] [Full Text] [Related]

  • 13. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
    Jacobs MR, Spangler SK, Appelbaum PC.
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
    Aldridge KE, Ashcraft D, O'Brien M, Sanders CV.
    Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
    [Abstract] [Full Text] [Related]

  • 16. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE, Gelfand M, Reller LB, Ayers LW, Pierson CL, Schoenknecht F, Tilton RC, Wilkins J, Henderberg A, Schiro DD.
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [Abstract] [Full Text] [Related]

  • 17. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE, Weeks LS, Stratton CW, Sanders CV.
    Diagn Microbiol Infect Dis; 1990 Apr; 13(4):311-6. PubMed ID: 2076592
    [Abstract] [Full Text] [Related]

  • 18. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K, Ueno K, Kato N, Muto Y, Bandoh K, Tanaka Y, Jotwani R, Goto M, Shimada K, Shimizu K.
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.